Physician profile
Amelia E Hendrickson
NPI 1235379074
$22,411.90
in general payments reported to CMS, 2019-2025
26 companies · $8,475 in 2025
The $8,475 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,207 · 2022: $3,858 · 2023: $3,675 · 2024: $4,198 · 2025: $8,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,044 · Consulting Fee: $5,395 · Travel and Lodging: $1,667 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,044.37 |
| Consulting Fee | $5,395.00 |
| Travel and Lodging | $1,666.54 |
| Education | $241.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $6,629.55 | 2022-2025 | Tremfya |
| Pfizer INC. | $4,999.09 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,354.32 | 2021-2025 | |
| Abbvie INC. | $1,297.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,275.44 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $1,120.49 | 2022-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,042.10 | 2022-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $733.66 | 2022-2025 | Saphnelo |
| Genzyme Corporation | $489.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $445.41 | 2021-2025 | Orencia |
| Glaxosmithkline, LLC. | $385.86 | 2022-2025 | Benlysta, Nucala |
| Lilly USA, LLC | $294.71 | 2022-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $215.19 | 2022-2024 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.46 | 2023-2025 | Ofev, Cyltezo, Spevigo |
| Sobi, INC | $177.89 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $148.86 | 2022-2025 | Renflexis, Hadlima |
| Radius Health, INC. | $142.09 | 2023-2025 | Tymlos |
| Sandoz INC. | $135.51 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $112.02 | 2023-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $58.45 | 2024-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $51.52 | 2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $36.87 | 2024-2025 | Actemra |
| Kyowa Kirin, INC. | $19.38 | 2023 | Crysvita |
| Invivyd INC | $17.21 | 2025 | Pemgarda |
| Fresenius Kabi USA, LLC | $16.92 | 2023 | Idacio |
| Teva Pharmaceuticals USA, INC. | $15.32 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Hendrickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.